Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.

ABSTRACT: Rational modulation of the immune response with biologics represents one of the most promising and active areas for the realization of new therapeutic strategies. In particular, the use of function blocking monoclonal antibodies targeting checkpoint inhibitors such as CTLA-4 and PD-1 have proven to be highly effective for the systemic activation of the human immune system to treat a wide range of cancers. Ipilimumab is a fully human antibody targeting CTLA-4 that received FDA approval for the treatment of metastatic melanoma in 2011. Ipilimumab is the first-in-class immunotherapeutic for blockade of CTLA-4 and significantly benefits overall survival of patients with metastatic melanoma. Understanding the chemical and physical determinants recognized by these mAbs provides direct insight in

SUBMITTER: Ramagopal UA 

PROVIDER: S-EPMC5448203 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature